5 Best Vaccine Stocks To Buy Now

In this article, we will discuss the 5 best vaccine stocks to buy now. If you want to explore similar stocks, you can also read 10 Best Vaccine Stocks To Buy Now.

5. Amgen, Inc. (NASDAQ:AMGN)

Number of Hedge Fund Holders: 55

Amgen, Inc. (NASDAQ:AMGN) is a large, diversified biotech company with multiple blockbuster drugs and a strong pipeline of new drugs in development. Amgen, Inc. (NASDAQ:AMGN) has a strong track record of success in clinical trials and commercializing new drugs. The company has a large, global sales force and a strong brand. The stock is one of the best vaccine stocks to buy now.

On October 20, Amgen, Inc. (NASDAQ:AMGN) announced that it has acquired ChemoCentryx for $52 per share in cash, for a transaction amount of $3.7 billion. ChemoCentryx is a biopharmaceutical company that is involved in the research and development of therapies for inflammatory and autoimmune diseases and cancer.

On October 12, Barclays analyst Carter Gould revised his price target on Amgen, Inc. (NASDAQ:AMGN) to $234 from $236 and maintained an Equal Weight rating on the shares. This October, Morgan Stanley analyst Matthew Harrison upgraded Amgen, Inc. (NASDAQ:AMGN) to Overweight from Equal Weight and raised his price target on the stock to $279 from $257.

At the close of Q2 2022, 55 hedge funds were bullish on Amgen, Inc. (NASDAQ:AMGN) and held stakes worth $2.17 billion in the company. This is compared to 56 positions in the previous quarter with stakes of $1.88 billion. As of June 30, Two Sigma Advisors is the top investor in Amgen, Inc. (NASDAQ:AMGN) and has stakes worth $404 million in the company.

Here is what Smead Capital Management had to say about Amgen Inc. (NASDAQ:AMGN) in its third-quarter 2022 investor letter:

“Two things are very noticeable right off the top. First, sometimes you have to be happy losing less in a bear market environment so that you have more of your capital to grow in the next bull market. We are never really happy losing money. Second, 2022 is likely to be our third year of existence as a fund to lose money for the year. This year would join 2008 and 2018 in this undistinguished category. Our biggest detractors was dominated by  Amgen (NASDAQ:AMGN). Consumer/investor fears about media and e-commerce hit WBD and EBAY and profit taking in Amgen came from early 2022 strength.”